Venture Capital Firm Bets Big on AI Drug Discovery Innovation

The pharmaceutical sector is at the cross-section at which artificial intelligence is reducing the decades of drug development processes to a few months. Being a venture capital firm that pays close attention to deeptech innovations, we have seen an earthquake in the way investors treat companies based on scientific breakthroughs. Especially the recent injection of $45 million into the AI-for-science platform ChemLex, which opens its global headquarters in Singapore, is a classical example of the transformative trend that attracts the attention of institutional investors around the globe.

The new method of ChemLex is a 24/7 autonomous chemistry system that fundamentally rebirths the conventional lab working methods. This autonomous laboratory vision is not a mere improvement over time, but a paradigm shift. The entire synthesis line on the platform operates fully automated, with experiments being automatically captured in real-time and converted into a continuous workflow transforming chemical discovery into a continuous workflow, as opposed to a start-stop process. The business case to venture capital companies looking at opportunities in the space is simple, less time-to-market, increased cost-efficiency, and a never-before-seen scalability in pharmaceutical research.

The market trend is one of the strongest things about this to the investors. According to industry analysts, the AI-assisted drug discovery market would soar by the year 2034, which is expected to be close to 50 billion dollars compared to the year 2024 at 3.6 billion dollars. This is an eye-opening forecast of growth that explains why the venture capital companies are furiously investing money into platforms that have proven to have a positive ROI. The commercial viability of their technology stack is confirmed by the fact that ChemLex has traction (over 70 customers, with six of the top ten pharmaceutical companies in the world) in less than three and a half years.

It is also a strategic move to base the operations in Singapore that offers yet another dimension of sophistication that the experienced venture capital firms value. Singapore represents a combination of sophisticated infrastructure, governmental encouragement of deeptech, and access to Asian markets that are all unique to the country. The memorandum of understanding with Experimental Drug Development Centre (EDDC) Singapore has given ChemLex a sandbox environment to fast-track next-generation small molecule drug discovery- a traditional example of public-private partnerships which de-risks early-stage development.

As a venture capital firm, this investment thesis is quite strong due to a number of reasons. To begin with, the platform is solving a very real pain point: pharmaceutical companies are putting billions of dollars a year into research and development with very low success rates. Second, the technology provides network effects, i.e. the more experiments are performed, the better the AI models are, which generates data most competitors can hardly create. Third, it is capital efficient when compared to the conventional biotech models which demand huge infrastructure expenditures.

The involvement of Granite Asia as the lead investor is an indication of confidence by the regional venture capital experts who are aware of the technology as well as the market dynamics. We have found ourselves echoing the words of our partner who said that AI-enabled chemistry would generate one of the most significant industrial shifts of the decade, and we are echoing these sentiments because we do the same thing internally at Evolve Venture Capital. Similar trends are present in our portfolio with AI native scientific platforms delivering 10x efficiency improvement compared to legacy methods.

The moral of the story to startup founders in this area is that venture capital firms are no longer placing bets on the science potential, but on execution speed and commercial momentum. The history of ChemLex, growing since its creation to being a provider of large pharma, proves the strength of breakthrough science and brutal operational focus combined. The 45 million round gives the company adequate runway to scale engineering talent and project pipeline; the company will be in a position to raise a Series B at much higher valuation multiples.

The wider implication is not only limited to the case of pharmaceuticals. Other autonomous lab approaches are appearing in materials science, specialty chemicals, and even climatic technology. As a venture capital firm, we are now following parallel trends in which AI-based synthesis platforms have the potential to bring a revolution in battery technology, carbon capture materials, and more sophisticated polymers. The next variant of deeptech ventures, which can create venture-level returns and address the most urgent problems humanity faces, is the ChemLex model the merging of software margins with the real world.

The investors must observe the changing due diligence structure of such deals. The conventional biotech metrics such as IP portfolios and the level of clinical trials are still of importance, but nowadays the VC firms are focusing on the speed of data production, enhancing the precision of algorithms as well as the risk of concentration among customers. The capability to show observable speed in time of discovery has become the new gold standard.

These are the very attributes that we focus on at Evolve Venture Capital in our Deeptech Investment Focus. We feel that the interaction between AI and hard sciences will establish category-defining businesses in the next decade. Our Portfolio Companies have some platforms that have used similar approaches of autonomous systems to other nearby industries that confirm our hypothesis that autonomous automation of scientific processes is the next significant innovation wave.

Evolve Venture Capital has offered a Financial Advisor Insight:

As an investor who plans to be exposed to AI-based drug discovery, we would advise to take a diversified strategy along the value chain. Platform company investments Direct venture investments in platform companies such as ChemLex have asymmetric upside, but demand comprehensive technical due diligence. Otherwise, there are publicly traded pharma companies that actively use AI platforms to partner with- these offer exposure with a lower risk profile. Our Venture Capital Fund Access program provides select exposure to established deeptech firms in late-stage to a liquidity event and works best with high-net-worth individuals. The trick is that it is not a niche movement but a reenergying of the basic mechanics of science, which results in generational wealth-generating dynamics of patient capital.

Contact Information: